All News

RheumNow Podcast square

ACR Award Winners (10.21.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlighted discussion of implantable stimulators, urine proteomics and gut-immune responses to Prevotella in RA.

Read Article
covid.corona

Vaccination Cut Long COVID Risk for Rheum Patients

MedPage Today

Patients with rheumatologic conditions who developed breakthrough COVID-19 infection after vaccination were less likely to suffer long-term symptoms than unvaccinated but otherwise similar patients, researchers said.

Read Article
Dr. Kent Kwoh and Researchers at the University of Arizona Arthritis Center have been awarded a $3.4 million grant from the National Institutes of Health to undertake a study that seeks to identify determinants of rapid knee deterioration in OA https://t.co/K9wxRzmVnw https://t.co/nM7ByxKikB

Links:

Dr. John Cush RheumNow ( View Tweet)
Anakinra in Pericarditis: A Systematic Review (comprehensive, full read) -Options include steroids, colchicine, NSAIDs, pleuropericardial window, IL-1 inhibitors. ANAKINRA - 11 studies, 259 pts, all showing significant rapid resolution. https://t.co/mEkaa7Yjt1 https://t.co/BaMYHiG5Pb

Links:

Dr. John Cush RheumNow ( View Tweet)
Highlights from the @ACRheum Kawasaki Disease Guidelines 🥇IVIG is mainstay therapy (2 g/kg) 👶🏼 Use ASA in acute KD 🗣Refractory cases may require steroids or additional immunosuppression 🫀Get echos on all patients to assess for coronary aneurysms

Catherine Sims, MD DrCassySims ( View Tweet)

Tawanese claims analysis of 10,857 RA pts shows lower CVA rates when taking Celebrex (5.95% vs 9.72% not taking) or Etoricoxib (2.69% vs 8.51% not taking). Both Celebrex/Etoricoxib significantly reduced stroke risk p < 0.001 https://t.co/6idrH9g0LJ https://t.co/d80bEtsP7k

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approves RINVOQ (upadacitinib) for the treatment of Active Non-Radiographic Axial Spondyloarthritis https://t.co/DMuQFjFdrf https://t.co/zLsniZ2zOg

Links:

Dr. John Cush RheumNow ( View Tweet)
Health Canada has approved EVUSHELD to treat COVID-19 in immunocompromised patients (it was previously approved to prevent COVID) https://t.co/ePgd4DjTka https://t.co/whgSM3ce7Q

Links:

Dr. John Cush RheumNow ( View Tweet)
Follow us for real time coverage #ACR2022 https://t.co/5CBdiKWdKM
Dr. John Cush RheumNow ( View Tweet)

“If you torture the data long enough it will confess” -Ronald Coase (economist) https://t.co/ZGivhUWLZW

Dr. John Cush RheumNow ( View Tweet)

How do Pts check Temps? Paired oral & temporal temps in 2031 Blacks & 2344 Whites: / whites showed no diff (36.97 vs 36.95°C), but signif diff in blacks (36.98 vs 37.05). Fever seen in 10.2-10.8% Whites, but 10.1% (temporal), 13.2% (oral) in Blacks https://t.co/D4XowfsYXD https://t.co/LmvEnAVGbr

Links:

Dr. John Cush RheumNow ( View Tweet)
Pregnancy Outcomes with Belimumab A study of SLE pregnancies exposed to belimumab (BEL) shows and expected rate of pregnancy loss but a variable rate of birth defects. https://t.co/cXm58iSmVc https://t.co/Hdg6Qg1uHE

Links:

Dr. John Cush RheumNow ( View Tweet)
Prevotella Immune Response in Both Pre-Clinical & Established RA In a recent analysis published in Arthritis & Rheumatology, people at risk for RA and those with the disease had elevated blood levels of antibodies against a Prevotella copri (Pc). https://t.co/6zArTx4XlM https://t.co/9UIk2OOhXq

Links:

Dr. John Cush RheumNow ( View Tweet)
Difficult to treat RA (D2T-RA) study of 48 D2T-145 non-D2T-RA pts. D2T-RA was predicted by Not starting MTX w/in 3 mos (17% vs 33% non-D2T-RA;p= 0.011) &being on steroids > 6 mos (71% vs 34%, p< 0.001). https://t.co/Ugbr7z7mia https://t.co/TCU7wSfMrS

Links:

Dr. John Cush RheumNow ( View Tweet)
mRNA COVID vaccine study from Vaccine Safety Datalink shows risk of myocarditis/pericarditis 0-7d post Vax (ages 5-39) is ~1/200K doses (1st dose), 1/ 30K(2nd dose), 1/50K (1st booster); w/ higher risk in adolescent males https://t.co/J1u038qxB7 https://t.co/vEUNbOvEQf

Links:

Dr. John Cush RheumNow ( View Tweet)

Anakinra in Pericarditis: A Systematic Review (comprehensive, full read) -Options include steroids, colchicine, NSAIDs, pleuropericardial window, IL-1 inhibitors. ANAKINRA - 11 studies, 259 pts, all showing significant rapid resolution. https://t.co/rcnTPkDTjq https://t.co/RbW1fPSjfU

Links:

Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine Dosing and SLE Flares A cohort study examining HCQ dosing in patients with SLE suggests that HCQ doses of 5 mg/kg per day or less, was associated with a higher risk of lupus flares, including moderate or severe lupus flares. https://t.co/UeIZ70zRnt https://t.co/tGrBSydvKB

Links:

Dr. John Cush RheumNow ( View Tweet)
Top Tweet of September: Gout: diagnosis and management—summary of NICE guidance https://t.co/CWg4otNBVv https://t.co/wRcjnC59eL

Links:

Dr. John Cush RheumNow ( View Tweet)
Long COVID study (54 studies, 2 databases, 1.2 million pts) showed at least 1 in 3 reported Long COVID Sx clusters (fatigue, bodily pain, mood swings, cognitive or resp Sxs), more common in women <20 yrs, w/ duration 9 mos in Hosp pts https://t.co/vuJrpWizzr https://t.co/e58J8rctEC

Links:

Dr. John Cush RheumNow ( View Tweet)
Spinal cord stimulation is a $2-3billion market, despite limited efficacy. A placebo controlled trial of spinal cord burst stimulation, in 50 pts w/ chr radicular pain after lumbar surgery, showed no significant benefit in back pain–related disability. https://t.co/aRN5sRbqFx https://t.co/A37LWaYEGw

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×